109 related articles for article (PubMed ID: 25434721)
1. Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells.
Kuang Z; Huang Z; Li Y; Yang G; Liu M; Yuan H
Mol Med Rep; 2015 Apr; 11(4):2868-74. PubMed ID: 25434721
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells.
Schuetz JD; Schuetz EG; Thottassery JV; Guzelian PS; Strom S; Sun D
Mol Pharmacol; 1996 Jan; 49(1):63-72. PubMed ID: 8569713
[TBL] [Abstract][Full Text] [Related]
3. Statin regulation of CYP3A4 and CYP3A5 expression.
Willrich MA; Hirata MH; Hirata RD
Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
[TBL] [Abstract][Full Text] [Related]
4.
Yang W; Zhao H; Dou Y; Wang P; Chang Q; Qiao X; Wang X; Xu C; Zhang Z; Zhang L
Drug Metab Dispos; 2023 Apr; 51(4):492-498. PubMed ID: 36623883
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
Wang J; Buchman CD; Seetharaman J; Miller DJ; Huber AD; Wu J; Chai SC; Garcia-Maldonado E; Wright WC; Chenge J; Chen T
J Am Chem Soc; 2021 Nov; 143(44):18467-18480. PubMed ID: 34648292
[TBL] [Abstract][Full Text] [Related]
6. Inherent sex-dependent regulation of human hepatic CYP3A5.
Thangavel C; Boopathi E; Shapiro BH
Br J Pharmacol; 2013 Feb; 168(4):988-1000. PubMed ID: 22994453
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
8. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
9. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Hofman J; Vagiannis D; Chen S; Guo L
Chem Biol Interact; 2021 May; 340():109448. PubMed ID: 33775687
[TBL] [Abstract][Full Text] [Related]
10. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
Niwa T; Yasumura M; Murayama N; Yamazaki H
Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
12. Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism.
Collins JM; Wang D
Pharmacogenet Genomics; 2022 Jan; 32(1):16-23. PubMed ID: 34320606
[TBL] [Abstract][Full Text] [Related]
13. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2013 Jun; 41(6):1187-94. PubMed ID: 23491640
[TBL] [Abstract][Full Text] [Related]
15. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
16. Induction of cytochrome P450 3A by Shexiang Baoxin Pill and its main components.
Jiang B; Cai F; Gao S; Meng L; Liang F; Dai X; Xu W; Chen W
Chem Biol Interact; 2012 Jan; 195(2):105-13. PubMed ID: 22178124
[TBL] [Abstract][Full Text] [Related]
17. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
Vrzal R; Kubesova K; Pavek P; Dvorak Z
Toxicol Lett; 2010 Mar; 193(2):183-8. PubMed ID: 20080160
[TBL] [Abstract][Full Text] [Related]
18. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.
Uno Y; Matsushita A; Osada N; Uehara S; Kohara S; Nagata R; Fukuzaki K; Utoh M; Murayama N; Yamazaki H
Drug Metab Dispos; 2010 Feb; 38(2):209-14. PubMed ID: 19910514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
